GSK (LON:GSK) Is Paying Out A Dividend Of £0.15
Yahoo Finance · 3 hours ago
Search results
- 44.14Add to watchlist-0.01 (-0.02%)At close:4:00 PM EDTWed. May 8, 202444.25 +0.11 (+0.25%)Pre mkt:4:28 AM EDTThu. May 9, 2024Delayed Quote (USD) · Pre-Market Time
- Open44.23High44.29Low44.06
- Mkt Cap90.19BP/E (TTM)16.17Div & Yield1.50 & 3.41%
- Prev. Close44.1552 Wk. Low33.3352 Wk. High44.33
What analysts are sayingTop storiesRelated stocks
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United...
We are a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together.
Investors | GSK. 2024 First quarter announcement. We announced our first quarter 2024 results on Wednesday 1 May. Access our first quarter results and latest Annual Report below. Q1 2024 results Annual Report 2023 (PDF - 8.3MB) We’re confident in our future.
Get the latest GSK plc (GSK) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.
May 1, 2024 · Emma Walmsley, Chief Executive Officer, GSK: "We have made a strong start to 2024, with another quarter of excellent performance and continued pipeline progress, including positive data read outs for 4 phase III medicines. These, together with other R&D achievements, mean we have strengthened prospects for growth in all of our key therapeutic ...
Globally, our portfolio spans vaccines, specialty and general medicines, with R&D focused on science of the immune system, human genetics and advanced technologies. GSK has a significant footprint in the US across commercial, R&D, manufacturing, and corporate functions.
We are a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together. We prioritise innovation in vaccines and specialty medicines to prevent and treat disease. Download.
